Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-I and Trazodone for Insomnia Phenotypes
NCT06281756Phase 1Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Mar 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Insomnia comparing CBT-I then Placebo with CBT-I then Trazodone (2 arms). Primary endpoints: Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I) at 9 weeks, Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT) at 9 weeks and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
trazodone
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06281756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281756.